{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:13Z","timestamp":1787988013839,"version":"build-2784847793"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07954-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:56:49Z","timestamp":1781053009000},"page":"6610-6616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chr\u00f3nos and K\u00e1iros in theragnostics: re-assessing time toxicity in final-line radiopharmaceutical treatments"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-2263","authenticated-orcid":false,"given":"Ian","family":"Alberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Buchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"7954_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1967\/s002449912762","volume":"27","author":"S Retsas","year":"2024","unstructured":"Retsas S. Theranostics, theragnostics, or iama-gnostics? Hell J Nucl Med. 2024;27:253. https:\/\/doi.org\/10.1967\/s002449912762.","journal-title":"Hell J Nucl Med"},{"key":"7954_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11019-019-09898-3","volume":"22","author":"U Wiesing","year":"2019","unstructured":"Wiesing U. Theranostics: is it really a revolution? Evaluating a new term in medicine. Med Health Care Philos. 2019;22:593\u20137. https:\/\/doi.org\/10.1007\/s11019-019-09898-3.","journal-title":"Med Health Care Philos"},{"key":"7954_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med Off Publ Soc Nucl Med. 2017;58:85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7954_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.123.265670","volume":"64","author":"WA Weber","year":"2023","unstructured":"Weber WA, Barthel H, Bengel F, Eiber M, Herrmann K, Sch\u00e4fers M. What is theranostics? J Nucl Med Soc Nuclear Med. 2023;64:669\u201370. https:\/\/doi.org\/10.2967\/jnumed.123.265670.","journal-title":"J Nucl Med Soc Nuclear Med"},{"key":"7954_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1055\/a-1489-0375","volume":"60","author":"M Patt","year":"2021","unstructured":"Patt M, Bengel F, Essler M, Krause B-J, Kuwert T, Rahbar K, et al. Kamingespr\u00e4ch \u201e\u00a7 13 (2b) AMG in der nuklearmedizinischen Therapie\u201d \u2013 eine Follow-up-Veranstaltung der NuklearMedizin 2020 \u2013 Digital. Nuklearmedizin - NuclearMedicine. 2021;60:262\u20133. https:\/\/doi.org\/10.1055\/a-1489-0375.","journal-title":"Nuklearmedizin - NuclearMedicine"},{"key":"7954_CR6","doi-asserted-by":"publisher","unstructured":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine [Internet]. [cited 2025 Aug 14]. https:\/\/doi.org\/10.1056\/NEJMoa2107322. Accessed 14 Aug 2025","DOI":"10.1056\/NEJMoa2107322"},{"key":"7954_CR7","doi-asserted-by":"publisher","first-page":"100323","DOI":"10.1016\/j.jcpo.2022.100323","volume":"32","author":"C Wayant","year":"2022","unstructured":"Wayant C, Mohyuddin GR, Prasad V. The accelerated approval pathway in oncology: balancing the benefits and potential harms. J Cancer Policy. 2022;32:100323. https:\/\/doi.org\/10.1016\/j.jcpo.2022.100323.","journal-title":"J Cancer Policy"},{"key":"7954_CR8","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21:e146\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(19)30821-6.","journal-title":"Lancet Oncol"},{"key":"7954_CR9","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/RLU.0000000000003842","volume":"46","author":"H Rathke","year":"2021","unstructured":"Rathke H, Fuxius S, Giesel FL, Lindner T, Debus J, Haberkorn U, et al. Two tumors, one target: preliminary experience with 90Y-FAPI therapy in a patient with metastasized breast and colorectal cancer. Clin Nucl Med. 2021;46:842\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000003842.","journal-title":"Clin Nucl Med"},{"key":"7954_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnumed.119.241232","volume":"61","author":"J Calais","year":"2020","unstructured":"Calais J. FAP: The next billion dollar nuclear theranostics target? J Nucl Med Soc Nucl Med. 2020;61:163\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.241232.","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"7954_CR11","first-page":"1011","volume":"60","author":"D Kwon","year":"2019","unstructured":"Kwon D, Rousseau E, Lau J, Zhang Z, Merkens H, Gitschtaler K, et al. Radiotherapy of a CXCR4-Expressing Lymphoma Mouse Model with [177Lu]Lu-BL01. J Nucl Med Soc Nucl Med. 2019;60:1011\u20131011.","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"7954_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2967\/jnumed.121.262468","volume":"63","author":"J Ferdinandus","year":"2022","unstructured":"Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients. J Nucl Med Off Publ Soc Nucl Med. 2022;63:727\u201334. https:\/\/doi.org\/10.2967\/jnumed.121.262468.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7954_CR13","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Pabst KM, Kessler L, Fragoso Costa P, Ferdinandus J, Weber M, et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28:4346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1432.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"7954_CR14","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"key":"7954_CR15","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.2967\/jnumed.118.220558","volume":"60","author":"J Czernin","year":"2019","unstructured":"Czernin J, Sonni I, Razmaria A, Calais J. The future of nuclear medicine as an independent specialty. J Nucl Med. 2019;60:3S-12S. https:\/\/doi.org\/10.2967\/jnumed.118.220558.","journal-title":"J Nucl Med"},{"key":"7954_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2967\/jnumed.121.262190","volume":"62","author":"C Johannes","year":"2021","unstructured":"Johannes C, Ken H. The disappearing act of nuclear medicine in the Netherlands: just a new trick by the great Harry Houdini? J Nucl Med Soc Nucl Med. 2021;62:903\u20134. https:\/\/doi.org\/10.2967\/jnumed.121.262190.","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"7954_CR17","doi-asserted-by":"crossref","unstructured":"Smith JE. Time, Times, and the \u201cRight Time\u201d; \u2018Chronos\u2019 and \u2018Kairos.\u2019 The Monist. Oxford University Press; 1969;53:1\u201313.","DOI":"10.5840\/monist196953115"},{"key":"7954_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jamaoncol.2021.3600","volume":"7","author":"V Prasad","year":"2021","unstructured":"Fundytus A, Prasad V, Booth CM. Has the current oncology value paradigm forgotten patients\u2019 time?: too little of a good thing. JAMA Oncol. 2021;7:1757\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3600.","journal-title":"JAMA Oncol"},{"key":"7954_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol Wolters Kluwer. 1997;15:110\u20135. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.110.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"7954_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00259-025-07507-5","volume":"53","author":"L Evangelista","year":"2025","unstructured":"Evangelista L, Mansi L, Spadafora M. PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life. Eur J Nucl Med Mol Imaging. 2025;53:19\u201323. https:\/\/doi.org\/10.1007\/s00259-025-07507-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR21","doi-asserted-by":"publisher","first-page":"pkac071","DOI":"10.1093\/jncics\/pkac071","volume":"6","author":"DD Joyce","year":"2022","unstructured":"Joyce DD, Wallis CJD, Huang L-C, Hoffman KE, Zhao Z, Koyama T, et al. The association between financial toxicity and treatment regret in men with localized prostate cancer. JNCI Cancer Spectrum. 2022;6:pkac071. https:\/\/doi.org\/10.1093\/jncics\/pkac071.","journal-title":"JNCI Cancer Spectrum"},{"key":"7954_CR22","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM. The Time Toxicity of Cancer Treatment. J Clin Oncol Wolters Kluwer. 2022;40:1611\u20135. https:\/\/doi.org\/10.1200\/JCO.21.02810.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"7954_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00520-024-08487-2","volume":"32","author":"PL Quinn","year":"2024","unstructured":"Quinn PL, Saiyed S, Hannon C, Sarna A, Waterman BL, Cloyd JM, et al. Reporting time toxicity in prospective cancer clinical trials: A scoping review. Support Care Cancer. 2024;32:275. https:\/\/doi.org\/10.1007\/s00520-024-08487-2.","journal-title":"Support Care Cancer"},{"key":"7954_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2967\/jnumed.124.269203","volume":"66","author":"I Alberts","year":"2025","unstructured":"Alberts I, More S, Knapp K, Mei R, Fanti S, Mingels C, et al. Is long-axial-field-of-view PET\/CT cost-effective? An international health-economic analysis. J Nucl Med Off Publ Soc Nucl Med. 2025;66:954\u201360. https:\/\/doi.org\/10.2967\/jnumed.124.269203.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7954_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cardet","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, et al. Is Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol. 2021;79:413\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.043.","journal-title":"Eur Urol"},{"key":"7954_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.socscimed.2017.02.025","volume":"179","author":"B van den Berg","year":"2017","unstructured":"van den Berg B, Gafni A, Portrait F. Attributing a monetary value to patients\u2019 time: a contingent valuation approach. Soc Sci Med. 2017;179:182\u201390. https:\/\/doi.org\/10.1016\/j.socscimed.2017.02.025.","journal-title":"Soc Sci Med"},{"key":"7954_CR27","unstructured":"Health CA for D and T in. CADTH Reimbursement Recommendation: Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto) for mCRPC. <bound method Organization.get_name_with_acronym of <Organization: Canadian Agency for Drugs and Technologies in Health>>; 2023 [cited 2025 Aug 14]; https:\/\/canadacommons.ca\/artifacts\/4543998\/cadth-reimbursement-recommendation\/5367478\/. Accessed 14 Aug 2025"},{"key":"7954_CR28","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1007\/s00259-021-05620-9","volume":"49","author":"I Alberts","year":"2022","unstructured":"Alberts I, Mingels C, Zacho HD, Lanz S, Sch\u00f6der H, Rominger A, et al. Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. Eur J Nucl Med Mol Imaging. 2022;49:4252\u201361. https:\/\/doi.org\/10.1007\/s00259-021-05620-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1477-7525-1-80","volume":"1","author":"L Prieto","year":"2003","unstructured":"Prieto L, Sacrist\u00e1n JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80. https:\/\/doi.org\/10.1186\/1477-7525-1-80.","journal-title":"Health Qual Life Outcomes"},{"key":"7954_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175:1389\u201398. https:\/\/doi.org\/10.1001\/jamainternmed.2015.2829.","journal-title":"JAMA Intern Med"},{"key":"7954_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/009286150203600127","volume":"36","author":"O Chassany","year":"2002","unstructured":"Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related quality of life\u2014a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209\u201338. https:\/\/doi.org\/10.1177\/009286150203600127.","journal-title":"Drug Inf J"},{"key":"7954_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/cncr.35075","volume":"130","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Hanna TP, Booth CM. Efficacy-effectiveness gaps in oncology: looking beyond survival. Cancer. 2024;130:335\u20138. https:\/\/doi.org\/10.1002\/cncr.35075.","journal-title":"Cancer"},{"key":"7954_CR33","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1200\/OP.22.00737","volume":"19","author":"A Gupta","year":"2023","unstructured":"Gupta A, O\u2019Callaghan CJ, Zhu L, Jonker DJ, Wong RPW, Colwell B, et al. Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial. JCO Oncol Pract Wolters Kluwer. 2023;19:e859-66. https:\/\/doi.org\/10.1200\/OP.22.00737.","journal-title":"JCO Oncol Pract Wolters Kluwer"},{"key":"7954_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.mcna.2020.06.002","volume":"104","author":"A Comer","year":"2020","unstructured":"Comer A, Fettig L, Torke AM. Identifying goals of care. Med Clin North Am. 2020;104:767\u201375. https:\/\/doi.org\/10.1016\/j.mcna.2020.06.002.","journal-title":"Med Clin North Am"},{"key":"7954_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7954_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.121.263638","volume":"63","author":"PH Kuo","year":"2022","unstructured":"Kuo PH, Benson T, Messmann R, Groaning M. Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial. J Nucl Med. 2022;63:816\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263638.","journal-title":"J Nucl Med"},{"key":"7954_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.123.266391","volume":"65","author":"A Farolfi","year":"2024","unstructured":"Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, et al. Differences and common ground in 177Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers. J Nucl Med. 2024;65:438\u201345. https:\/\/doi.org\/10.2967\/jnumed.123.266391.","journal-title":"J Nucl Med"},{"key":"7954_CR38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263159","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J. PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy. J Nucl Med. 2021;62:1489\u201391. https:\/\/doi.org\/10.2967\/jnumed.121.263159.","journal-title":"J Nucl Med"},{"key":"7954_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2967\/jnumed.122.264741","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Hadaschik B, Fendler WP, Kuo PH, Herrmann K. Is 18F-FDG PET needed to assess 177Lu-PSMA therapy eligibility? A VISION-like, single-center analysis. J Nucl Med Off Publ Soc Nucl Med. 2023;64:731\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.264741.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7954_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00259-022-05961-z","volume":"50","author":"I Alberts","year":"2023","unstructured":"Alberts I, Schepers R, Zeimpekis K, Sari H, Rominger A, Afshar-Oromieh A. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET\/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50:951\u20136. https:\/\/doi.org\/10.1007\/s00259-022-05961-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40644-024-00773-w","volume":"24","author":"D Ventura","year":"2024","unstructured":"Ventura D, Rassek P, Schindler P, Akkurt BH, Bredensteiner L, B\u00f6gemann M, et al. Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET. Cancer Imaging. 2024;24:126. https:\/\/doi.org\/10.1186\/s40644-024-00773-w.","journal-title":"Cancer Imaging"},{"key":"7954_CR42","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49:4271\u201381. https:\/\/doi.org\/10.1007\/s00259-022-05882-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR43","doi-asserted-by":"publisher","unstructured":"Zhang J, Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Langbein T, et al. 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney. J Nucl Med [Internet]. Soc Nucl Med; 2019 [cited 2025 Aug 14]; https:\/\/doi.org\/10.2967\/jnumed.118.223149.","DOI":"10.2967\/jnumed.118.223149"},{"key":"7954_CR44","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"7954_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5489\/cuaj.1146","volume":"3","author":"U Emmenegger","year":"2009","unstructured":"Emmenegger U, Ko Y-J. PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations. Can Urol Assoc J. 2009;3:375\u20136. https:\/\/doi.org\/10.5489\/cuaj.1146.","journal-title":"Can Urol Assoc J"},{"key":"7954_CR46","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","volume":"65","author":"S Yadav","year":"2024","unstructured":"Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, et al. Impact of posttreatment SPECT\/CT on patient management during 177Lu-PSMA-617 radiopharmaceutical therapy. J Nucl Med. 2024;65:1395\u2013401. https:\/\/doi.org\/10.2967\/jnumed.124.267955.","journal-title":"J Nucl Med"},{"key":"7954_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2967\/jnumed.124.268325","volume":"66","author":"L Emmett","year":"2025","unstructured":"Emmett L. SPECT deserves RESPECT: the potential of SPECT\/CT to optimize patient outcomes with theranostics therapy. J Nucl Med. 2025;66:349\u201350. https:\/\/doi.org\/10.2967\/jnumed.124.268325.","journal-title":"J Nucl Med"},{"key":"7954_CR48","doi-asserted-by":"publisher","first-page":"111774","DOI":"10.1016\/j.ejrad.2024.111774","volume":"181","author":"F Kleiburg","year":"2024","unstructured":"Kleiburg F, de Geus-Oei LF, Luelmo SAC, Spijkerman R, Goeman JJ, Toonen FAJ, et al. PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients. Eur J Radiol. 2024;181:111774. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111774.","journal-title":"Eur J Radiol"},{"key":"7954_CR49","doi-asserted-by":"publisher","first-page":"S970","DOI":"10.1016\/j.annonc.2024.08.1689","volume":"35","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Gafita A, Bressel M, Alipour R, Levy S, Emmett L, et al. 1608P prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET\/CT for response evaluation: Analysis from the PRINCE trial. Ann Oncol. 2024;35:S970. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1689.","journal-title":"Ann Oncol"},{"key":"7954_CR50","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, et al. SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy. J Nucl Med. 2023;64:1417\u201323. https:\/\/doi.org\/10.2967\/jnumed.123.265952.","journal-title":"J Nucl Med"},{"key":"7954_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557\u201365. https:\/\/doi.org\/10.1200\/JCO.2015.63.0830.","journal-title":"J Clin Oncol"},{"key":"7954_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2967\/jnumed.122.264298","volume":"64","author":"T Beyer","year":"2023","unstructured":"Beyer T, Czernin J, Freudenberg L, Giesel F, Hacker M, Hicks RJ, et al. A 2022 international survey on the status of prostate cancer theranostics. J Nucl Med. 2023;64:47\u201353. https:\/\/doi.org\/10.2967\/jnumed.122.264298.","journal-title":"J Nucl Med"},{"key":"7954_CR53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, V\u00f6lter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767\u201374. https:\/\/doi.org\/10.2967\/jnumed.122.264594.","journal-title":"J Nucl Med"},{"key":"7954_CR54","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-014-2824-5","volume":"41","author":"L Strigari","year":"2014","unstructured":"Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976\u201388. https:\/\/doi.org\/10.1007\/s00259-014-2824-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR55","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1007\/s00259-020-05147-5","volume":"48","author":"FA Verburg","year":"2021","unstructured":"Verburg FA, Nonnekens J, Konijnenberg MW, de Jong M. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the \u201cHoly Gray\u201d in radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:2680\u20132. https:\/\/doi.org\/10.1007\/s00259-020-05147-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR56","doi-asserted-by":"publisher","unstructured":"Sartor O, Emmett LM, Herrman K. Routine Dosimetry: Proceed with Caution. J Nucl Med [Internet]. Society of Nuclear Medicine; 2025 [cited 2025 Oct 6]; https:\/\/doi.org\/10.2967\/jnumed.125.269867.","DOI":"10.2967\/jnumed.125.269867"},{"key":"7954_CR57","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00259-017-3820-3","volume":"44","author":"F Giammarile","year":"2017","unstructured":"Giammarile F, Muylle K, Delgado Bolton R, Kunikowska J, Haberkorn U, Oyen W. Dosimetry in clinical radionuclide therapy: the devil is in the detail. Eur J Nucl Med Mol Imaging. 2017;44:2137\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3820-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7954_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/HP.0000000000001644","volume":"124","author":"DJ Cappon","year":"2023","unstructured":"Cappon DJ, Fang S, Berry K, Capone G, Carlton GL, Chr\u00e9tien M, et al. Clinical best practices for radiation safety during lutetium-177 therapy. Health Phys. 2023;124:139. https:\/\/doi.org\/10.1097\/HP.0000000000001644.","journal-title":"Health Phys"},{"key":"7954_CR59","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.2967\/jnumed.124.268062","volume":"65","author":"F Zagni","year":"2024","unstructured":"Zagni F, Vetrone L, Farolfi A, Vadal\u00e0 M, Rizzini EL, Golemi A, et al. Feasibility of 177Lu-PSMA administration as outpatient procedure for prostate cancer. J Nucl Med. 2024;65:1848\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.268062.","journal-title":"J Nucl Med"},{"key":"7954_CR60","doi-asserted-by":"publisher","unstructured":"Ideguchi R, Toilybayeva A, Toya R, Yokoyama S, Kudo T. Assessment of environmental radioactive contamination in radiation therapy rooms: comparison between therapy after Lu-177 DOTATATE and I-131. Ann Nucl Med [Internet]. 2026 [cited 2026 Apr 15]; https:\/\/doi.org\/10.1007\/s12149-026-02183-3.","DOI":"10.1007\/s12149-026-02183-3"},{"key":"7954_CR61","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MNM.0000000000000232","volume":"36","author":"C Olmstead","year":"2015","unstructured":"Olmstead C, Cruz K, Stodilka R, Zabel P, Wolfson R. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol. Nucl Med Commun. 2015;36:129. https:\/\/doi.org\/10.1097\/MNM.0000000000000232.","journal-title":"Nucl Med Commun"},{"key":"7954_CR62","doi-asserted-by":"publisher","first-page":"1355.2","DOI":"10.2967\/jnumed.117.190983","volume":"58","author":"P Zanotti-Fregonara","year":"2017","unstructured":"Zanotti-Fregonara P, Hindie E. Linear no-threshold hypothesis at the hospital: When radioprotection becomes a nosocomial hazard. J Nucl Med. 2017;58:1355.2-1355. https:\/\/doi.org\/10.2967\/jnumed.117.190983.","journal-title":"J Nucl Med"},{"key":"7954_CR63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40658-025-00776-x","volume":"12","author":"D Levart","year":"2025","unstructured":"Levart D, Wicks S, Heraghty N, Kalogianni E, Mulholland N. Radiation exposure to families of patients following administration of 177Lu-DOTATATE for the treatment of metastatic neuroendocrine tumours. EJNMMI Phys. 2025;12:94. https:\/\/doi.org\/10.1186\/s40658-025-00776-x.","journal-title":"EJNMMI Phys"},{"key":"7954_CR64","doi-asserted-by":"publisher","first-page":"6440","DOI":"10.1200\/JCO.2005.02.3259","volume":"23","author":"BD Bultz","year":"2005","unstructured":"Bultz BD, Carlson LE. Emotional distress: the sixth vital sign in cancer care. J Clin Oncol. 2005;23:6440\u20131. https:\/\/doi.org\/10.1200\/JCO.2005.02.3259. (Wolters Kluwer).","journal-title":"J Clin Oncol"},{"key":"7954_CR65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.clon.2010.06.006","volume":"22","author":"S Tyldesley","year":"2010","unstructured":"Tyldesley S, McGahan C. Utilisation of radiotherapy in rural and urban areas in British Columbia compared with evidence-based estimates of radiotherapy needs for patients with breast, prostate and lung cancer. Clin Oncol. 2010;22:526\u201332. https:\/\/doi.org\/10.1016\/j.clon.2010.06.006.","journal-title":"Clin Oncol"},{"key":"7954_CR66","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1200\/JOP.19.00328","volume":"16","author":"EM Bange","year":"2020","unstructured":"Bange EM, Doucette A, Gabriel PE, Porterfield F, Harrigan JJ, Wang R, et al. Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma. JCO Oncol Pract. 2020;16:e678\u201387. https:\/\/doi.org\/10.1200\/JOP.19.00328.","journal-title":"JCO Oncol Pract"},{"key":"7954_CR67","doi-asserted-by":"publisher","unstructured":"Unterrainer LM, Ruchalski K, Allen-Auerbach MS, Calais J, Benz MR. PSMA PET\/CT dual-time-point imaging: Nice to have or need to have? J Nucl Med [Internet]. Soc Nucl Med; 2024 [cited 2025 Aug 14]; https:\/\/doi.org\/10.2967\/jnumed.123.266722.","DOI":"10.2967\/jnumed.123.266722"},{"key":"7954_CR68","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/bmj.39384.467928.94","volume":"335","author":"J Curran","year":"2007","unstructured":"Curran J. The doctor, his patient and the illness. BMJ. 2007;335:941. https:\/\/doi.org\/10.1136\/bmj.39384.467928.94.","journal-title":"BMJ"},{"key":"7954_CR69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jama.281.3.283","volume":"281","author":"MK Marvel","year":"1999","unstructured":"Marvel MK, Epstein RM, Flowers K, Beckman HB. Soliciting the patient\u2019s agendahave we improved? JAMA. 1999;281:283\u20137. https:\/\/doi.org\/10.1001\/jama.281.3.283.","journal-title":"JAMA"},{"key":"7954_CR70","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non\u2013small-cell lung cancer. N Engl J Med. 2010;363:733\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1000678.","journal-title":"N Engl J Med"},{"key":"7954_CR71","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.2967\/jnumed.124.268363","volume":"65","author":"J Calais","year":"2024","unstructured":"Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, et al. Best patient care practices for administering PSMA-targeted radiopharmaceutical therapy. J Nucl Med. 2024;65:1666\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.268363.","journal-title":"J Nucl Med"},{"key":"7954_CR72","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3978\/j.issn.2223-4683.2013.09.13","volume":"2","author":"MT Sanford","year":"2013","unstructured":"Sanford MT, Greene KL, Carroll PR. The argument for palliative care in prostate cancer. Transl Androl Urol. 2013;2:278\u201380. https:\/\/doi.org\/10.3978\/j.issn.2223-4683.2013.09.13.","journal-title":"Transl Androl Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07954-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:52Z","timestamp":1787986852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7954"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07954-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethics board approval was required for this commentary.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian Alberts reports speaker honoraria from Novartis. Ian Alberts and Christos Sachpekidis are members of the editorial board of this journal.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}